Search
Stakeholders
Academia
Employers
Health System
Payers
Providers
Topics
Clinical
Healthcare Cost
Healthcare Delivery
Insurance
Policy
Technology
Value-Based Care
Institute for Value-Based Medicine
All Coverage
Event Coverage
Interviews
News
About AJMC
AJMC Journals
Anniversary
Author Forms
Authors
Nominate a Rising Leader
News
All News
Partners
Press Releases
Media
Clinical Spotlight
Guidelines
Insights
Interviews
Managed Care Cast
Medical World News
Microsites
OnLocation
Peer Exchange
Post Conference Perspectives
Sponsored
Stakeholder Summit
Webinars
Week in Review
Conferences
Conference Coverage
Conference Listing
Journals
All Journals
The American Journal of Managed Care
The American Journal of Accountable Care
Evidence-Based Oncology
Evidence-Based Diabetes Management
Supplements and Featured Publications
Compendia
Alternative Payment Models
Autoimmune
Breast Cancer
Cardiovascular
Chronic Kidney Disease
Clinical Pathways
Colorectal Cancer
COPD
Diabetes
Employers
Heart Failure
Hematology
HIV
Immuno-Oncology
Inflammation
Leukemia and Lymphoma
Lung Cancer
Migraine
Multiple Sclerosis
Myelodysplastic Syndromes
Oncology
Ophthalmology
Ovarian Cancer
Pain Management
Parkinson Disease
Population Health
Precision Oncology
Prostate Cancer
Pulmonary Arterial Hypertension
Rare Disease
Reimbursement
Respiratory
Rheumatology
RNA Interference
Sleep
Spinal Muscular Atrophy
Events
Events
Upcoming Webinars
Resources
Education
Formulary Central
Resources
Video Poster Detail
Subscribe
eNewsletter
Search
Stakeholders
Academia
Employers
Health System
Payers
Providers
Topics
Clinical
Healthcare Cost
Healthcare Delivery
Insurance
Policy
Technology
Value-Based Care
Institute for Value-Based Medicine
All Coverage
Event Coverage
Interviews
News
About AJMC
AJMC Journals
Anniversary
Author Forms
Authors
Nominate a Rising Leader
Insights
All Topics
Autoimmune
Biosimilars
Cardiovascular
Clinical
Clinical Pathways
Diabetes
Employers
Employers
Healthcare Cost
Healthcare Delivery
Heart Failure
Hematology
Immuno-Oncology
Inflammation
Insurance
Multiple Sclerosis
Oncology
Ophthalmology
Policy
Rare Disease
Respiratory
Rheumatology
Value Based Care
Apply
Heart Failure With Preserved Ejection Fraction: Current Status and Future Opportunities
EP. 1:
Heart Failure Clinical and Economic Burden
EP. 1:
Heart Failure Clinical and Economic Burden
EP. 2:
The Progressive Nature of Heart Failure
EP. 2:
The Progressive Nature of Heart Failure
EP. 3:
Link Between LVEF, NT-ProBNP and Cardiac Remodeling
EP. 3:
Link Between LVEF, NT-ProBNP and Cardiac Remodeling
EP. 4:
Improved Understanding of Heart Failure
EP. 4:
Improved Understanding of Heart Failure
EP. 5:
Treatment Goals for Patients With Heart Failure
EP. 5:
Treatment Goals for Patients With Heart Failure
EP. 6:
The HFrEF Standard of Care
EP. 6:
The HFrEF Standard of Care
EP. 7:
Heart Failure Management Unmet Needs
EP. 7:
Heart Failure Management Unmet Needs
EP. 8:
Utilization Management Strategies for Appropriate Treatment
EP. 8:
Utilization Management Strategies for Appropriate Treatment
EP. 9:
Challenges in the Management of HFpEF
EP. 9:
Challenges in the Management of HFpEF
EP. 10:
Differences in Standard of Care: HFpEF vs HFrEF
EP. 10:
Differences in Standard of Care: HFpEF vs HFrEF
EP. 11:
Ensuring Timely and Appropriate Access to Therapy
EP. 11:
Ensuring Timely and Appropriate Access to Therapy
EP. 12:
Differences in Economic Burden: HFpEF and HFrEF
EP. 12:
Differences in Economic Burden: HFpEF and HFrEF
EP. 13:
PROVE-HF Trial Overview
EP. 13:
PROVE-HF Trial Overview
EP. 14:
PARAGON-HF Trial Overview
EP. 14:
PARAGON-HF Trial Overview
EP. 15:
Recent Findings from the PARALLAX Study
EP. 15:
Recent Findings from the PARALLAX Study
EP. 16:
Promising Findings From the TOPCAT Study
EP. 16:
Promising Findings From the TOPCAT Study
EP. 17:
Differences in Leading Treatments for Heart Failure
EP. 17:
Differences in Leading Treatments for Heart Failure
EP. 18:
When to Add an SGLT2 Inhibitor to Treatment Regimen
EP. 18:
When to Add an SGLT2 Inhibitor to Treatment Regimen
New Directions in Chemotherapy-Induced Neutropenia
EP. 1:
Facts About Chemotherapy-Induced Neutropenia
EP. 1:
Facts About Chemotherapy-Induced Neutropenia
EP. 2:
Chemotherapy-Induced Neutropenia: Impact on Cancer Care
EP. 2:
Chemotherapy-Induced Neutropenia: Impact on Cancer Care
EP. 3:
Monitoring for Chemotherapy-Induced Neutropenia
EP. 3:
Monitoring for Chemotherapy-Induced Neutropenia
EP. 4:
Considerations for Chemotherapy-Induced Neutropenia Prophylaxis
EP. 4:
Considerations for Chemotherapy-Induced Neutropenia Prophylaxis
EP. 5:
Chemotherapy-Induced Neutropenia Prophylaxis: Standard of Care
EP. 5:
Chemotherapy-Induced Neutropenia Prophylaxis: Standard of Care
EP. 6:
CIN Prophylaxis: Treating With G-CSFs
EP. 6:
CIN Prophylaxis: Treating With G-CSFs
EP. 7:
Plinabulin With G-CSF Treatment for CIN Prophylaxis
EP. 7:
Plinabulin With G-CSF Treatment for CIN Prophylaxis
EP. 8:
CIN Prophylaxis: NCCN’s Reactions to COVID-19
EP. 8:
CIN Prophylaxis: NCCN’s Reactions to COVID-19
EP. 9:
Chemotherapy-Induced Neutropenia: Financial Burden
EP. 9:
Chemotherapy-Induced Neutropenia: Financial Burden
EP. 10:
Health Plans React to Chemotherapy-Induced Neutropenia
EP. 10:
Health Plans React to Chemotherapy-Induced Neutropenia
EP. 11:
Reducing the Risk of Chemotherapy-Induced Neutropenia
EP. 11:
Reducing the Risk of Chemotherapy-Induced Neutropenia
EP. 12:
At-Home Administration of CIN Prophylaxis
EP. 12:
At-Home Administration of CIN Prophylaxis
EP. 13:
Coverage for Chemotherapy-Induced Neutropenia
EP. 13:
Coverage for Chemotherapy-Induced Neutropenia
CAR T-Cell Therapy for the Management of Multiple Myeloma
EP. 1:
Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
EP. 1:
Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
EP. 2:
Healthcare Utilization for Relapsed/Refractory MM Patients
EP. 2:
Healthcare Utilization for Relapsed/Refractory MM Patients
EP. 3:
Treatment Gaps in Relapsed/Refractory MM
EP. 3:
Treatment Gaps in Relapsed/Refractory MM
EP. 4:
A Better Understanding of Relapsed/Refractory MM
EP. 4:
A Better Understanding of Relapsed/Refractory MM
EP. 5:
CAR T-Cell Therapy in Relapsed/Refractory MM
EP. 5:
CAR T-Cell Therapy in Relapsed/Refractory MM
Defining Value for the Treatment of Brain Metastases in Metastatic HER2-Positive Breast Cancer
EP. 1:
Progression of HER2+ mBC
EP. 1:
Progression of HER2+ mBC
EP. 2:
HER2+ mBC: Diagnosing Patients With Brain Mets
EP. 2:
HER2+ mBC: Diagnosing Patients With Brain Mets
EP. 3:
Monitoring Brain Mets in HER2+ mBC
EP. 3:
Monitoring Brain Mets in HER2+ mBC
EP. 4:
Healthcare Utilization for HER2+ mBC With Brain Mets
EP. 4:
Healthcare Utilization for HER2+ mBC With Brain Mets
EP. 5:
Treatment Beyond Second-line Therapy in HER2+ mBC
EP. 5:
Treatment Beyond Second-line Therapy in HER2+ mBC
EP. 6:
Managing At-Risk Patients for Brain Mets in HER2+ mBC
EP. 6:
Managing At-Risk Patients for Brain Mets in HER2+ mBC
EP. 7:
HER2CLIMB Study
EP. 7:
HER2CLIMB Study
EP. 8:
Phase 2 LANDSCAPE Trial
EP. 8:
Phase 2 LANDSCAPE Trial
EP. 9:
Phase 3 NALA Study
EP. 9:
Phase 3 NALA Study
EP. 10:
Phase 2 DESTINY-Breast01 Trial
EP. 10:
Phase 2 DESTINY-Breast01 Trial
EP. 11:
Value of Emerging Agents in HER2+ mBC
EP. 11:
Value of Emerging Agents in HER2+ mBC
EP. 12:
Sequencing HER2-targeted Agents in mBC
EP. 12:
Sequencing HER2-targeted Agents in mBC
EP. 13:
Approaching At-Risk Patients for Brain Mets in HER2+ mBC
EP. 13:
Approaching At-Risk Patients for Brain Mets in HER2+ mBC
EP. 14:
Impact of Early Identification of Brain Mets
EP. 14:
Impact of Early Identification of Brain Mets
EP. 15:
Patient-Centered Care for Treatment of Brain Mets
EP. 15:
Patient-Centered Care for Treatment of Brain Mets
EP. 16:
Payer Perspective: Impact of COVID-19 on Treatment of mBC
EP. 16:
Payer Perspective: Impact of COVID-19 on Treatment of mBC
EP. 17:
Impact of COVID-19 and Future of mBC Treatment
EP. 17:
Impact of COVID-19 and Future of mBC Treatment
Challenges and Opportunities for Patients With HIV During COVID-19
EP. 1:
The Impact of COVID-19 on the HIV Community
EP. 1:
The Impact of COVID-19 on the HIV Community
EP. 2:
HIV and Risk of COVID-19
EP. 2:
HIV and Risk of COVID-19
EP. 3:
Healthcare Disparities and HIV During COVID-19
EP. 3:
Healthcare Disparities and HIV During COVID-19
EP. 4:
Diagnosing HIV During COVID-19
EP. 4:
Diagnosing HIV During COVID-19
EP. 5:
HIV Prescribing Patterns During COVID-19
EP. 5:
HIV Prescribing Patterns During COVID-19
EP. 6:
Managing HIV During COVID-19
EP. 6:
Managing HIV During COVID-19
EP. 7:
PrEP Therapy for HIV and COVID-19
EP. 7:
PrEP Therapy for HIV and COVID-19
EP. 8:
PrEP Adherence During COVID-19
EP. 8:
PrEP Adherence During COVID-19
EP. 9:
HIV Treatment Adherence and COVID-19
EP. 9:
HIV Treatment Adherence and COVID-19
EP. 10:
Managing HIV In the Future: Lessons from COVID-19
EP. 10:
Managing HIV In the Future: Lessons from COVID-19
Current and Future Treatments for the Management of Myelodysplastic Syndrome
EP. 1:
An Overview of Myelodysplastic Syndrome
EP. 1:
An Overview of Myelodysplastic Syndrome
EP. 2:
Understanding Myelodysplastic Syndrome's Nature as Cancer
EP. 2:
Understanding Myelodysplastic Syndrome's Nature as Cancer
EP. 3:
Myelodysplastic Syndrome: Diagnosis and Risk Stratification
EP. 3:
Myelodysplastic Syndrome: Diagnosis and Risk Stratification
EP. 4:
Clinical Burden of Myelodysplastic Syndrome
EP. 4:
Clinical Burden of Myelodysplastic Syndrome
EP. 5:
Economic Burden of Myelodysplastic Syndrome
EP. 5:
Economic Burden of Myelodysplastic Syndrome
EP. 6:
Myelodysplastic Syndrome: Goals of Therapy
EP. 6:
Myelodysplastic Syndrome: Goals of Therapy
EP. 7:
MDS Management: Use of Bone Marrow Transplantation
EP. 7:
MDS Management: Use of Bone Marrow Transplantation
EP. 8:
Therapies and Treatment Regimens for MDS
EP. 8:
Therapies and Treatment Regimens for MDS
EP. 9:
Hypomethylating Agents in MDS Management
EP. 9:
Hypomethylating Agents in MDS Management
EP. 10:
MDS Management: Use of Transfusion Alongside HMAs
EP. 10:
MDS Management: Use of Transfusion Alongside HMAs
EP. 11:
Potential Complications of Transfusions in MDS Management
EP. 11:
Potential Complications of Transfusions in MDS Management
EP. 12:
MDS Management: Challenges With Chemotherapy
EP. 12:
MDS Management: Challenges With Chemotherapy
EP. 13:
MDS Management: ASCERTAIN Equivalence Study
EP. 13:
MDS Management: ASCERTAIN Equivalence Study
EP. 14:
Oral HMAs in MDS Management: Adherence and Accessibility
EP. 14:
Oral HMAs in MDS Management: Adherence and Accessibility
EP. 15:
Oral HMAs in MDS: Personal Experience and Future Directions
EP. 15:
Oral HMAs in MDS: Personal Experience and Future Directions
EP. 16:
MDS: Access to Care and Other Ongoing Challenges
EP. 16:
MDS: Access to Care and Other Ongoing Challenges
EP. 17:
Practical Advice for Managing Myelodysplastic Syndrome
EP. 17:
Practical Advice for Managing Myelodysplastic Syndrome